Investors of Hims & Hers Health, Inc. Have Chance to Lead Major Class Action Lawsuit

Investors Have a Chance to Lead Hims & Hers Class Action Lawsuit

In a recent development pertaining to Hims & Hers Health, Inc. (NYSE: HIMS), investors who have incurred significant losses can now take steps to lead a class action lawsuit against the company. Robbins Geller Rudman & Dowd LLP has announced this opportunity for purchasers or acquirers of Hims & Hers securities during the designated Class Period which spanned from August 4, 2025, to July 29, 2026. Those wishing to serve as lead plaintiffs must act before the deadline of November 2, 2026.

Overview of the Case

The class action lawsuit, titled Velanki v. Hims & Hers Health, Inc., accuses Hims & Hers and several of its executives of violating various components of the Securities Exchange Act of 1934. The allegations claim that during the Class Period, the company made misleading statements and failed to disclose critical information regarding its operations and user privacy practices.

Specifically, it is alleged that:
1. Misleading Health Information Sharing: Hims & Hers purportedly shared sensitive consumer health data with third-party advertising platforms, violating the trust of its users who were promised strict confidentiality.
2. Immediate Charging for Services: Despite claiming to provide personalized consultations, the company charged consumers for prescriptions almost instantly after they submitted their intake forms. This practice undermined the said user experience that Hims & Hers marketed.
3. Regulatory Scrutiny and Potential Liabilities: Due to the aforementioned practices, Hims & Hers might face regulatory investigations and financial penalties. This raised concerns about the integrity of the company's previous positive claims regarding its business operations and future potential.

The gravity of these allegations intensified following a lawsuit announcement by the Federal Trade Commission (FTC), which accused Hims & Hers of deceptive practices, specifically citing the unauthorized sharing of consumer health data and misleading billing and cancellation protocols. These issues contributed to a notable decline in the company’s stock price, resulting in a decrease of nearly 15% following the FTC's announcement.

The Class Action Process

According to the Private Securities Litigation Reform Act of 1995, any investor who has purchased Hims & Hers securities during the Class Period can seek to be appointed as lead plaintiff in the class action. This lead plaintiff designation is typically granted to the person or entity with the most substantial financial interest in the outcome, and who can adequately represent the interests of the class.

Leading the lawsuit involves acting on behalf of all affected investors, steering the litigation process, and selecting a law firm to handle the case. Notably, the ability to participate in any possible recovery does not depend on serving as the lead plaintiff.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is internationally recognized for representing investors in matters of securities fraud and shareholders’ rights litigation. The firm has achieved remarkable successes on behalf of its clients, recovering over $9 billion for investors in the past five years alone. As one of the largest plaintiffs' law firms globally, Robbins Geller continues to set standards in the legal industry with its track record.

For those who are interested in learning more about the class action or to participate, Robbins Geller offers information on their website and encourages potential lead plaintiffs to take action before the approaching deadline.

As the situation evolves, affected Hims & Hers investors are encouraged to stay informed and evaluate their options in light of these serious allegations and potential legal actions.